BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- BNTX BioNTech SE-9.2% 9d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that BioNTech SE belongs to, so it often moves with news about it.
- NBIX Neurocrine Biosciences+16.3% 7d
Neurocrine Biosciences is a peer of BioNTech SE in biological products, (no diagnostic substances); rivals often move on the same news.
- QGEN Qiagen N.V
Qiagen N.V is a peer of BioNTech SE in biological products, (no diagnostic substances); rivals often move on the same news.
- CRSP CRISPR Therapeutics AG-16.4% 30d
CRISPR Therapeutics AG is a peer of BioNTech SE in biological products, (no diagnostic substances); rivals often move on the same news.
- AMGN Amgen+10.3% 30d
Amgen is a peer of BioNTech SE in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+18.5% 30d
Gilead Sciences is a peer of BioNTech SE in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BNTX | -0.51% | +1.81% | base | -0.74% | +3.65% | -1.89% | +0.06% |
| XLV | -2.95% | -0.31% | base | -0.34% | +2.73% | +0.31% | +0.13% |
| NBIX | +0.43% | +0.69% | base | +13.30% | +14.21% | +9.94% | +13.24% |
| QGEN | -0.29% | +0.05% | base | +0.10% | +0.95% | +1.04% | -0.03% |
| CRSP | +3.04% | +8.60% | base | +0.08% | +3.64% | -2.87% | +0.22% |
| AMGN | -3.75% | -1.04% | base | -0.92% | +2.72% | -1.06% | -0.89% |
| GILD | -6.65% | -2.82% | base | -1.70% | +2.38% | -1.69% | -1.64% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks The Pharma Letter
Source: The Pharma Letter
Energy
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | -0.92% | final price |
| AMGN | the next day | +2.72% | final price |
| AMGN | two days later | -1.06% | final price |
| AMGN | three days later | -0.89% | final price |
| AMGN | three days earlier | -1.04% | final price |
| AMGN | five days earlier | -3.75% | final price |
| BNTX | that day | -0.74% | final price |
| BNTX | the next day | +3.65% | final price |
| BNTX | two days later | -1.89% | final price |
| BNTX | three days later | +0.06% | final price |
| BNTX | three days earlier | +1.81% | final price |
| BNTX | five days earlier | -0.51% | final price |
| CRSP | that day | +0.08% | final price |
| CRSP | the next day | +3.64% | final price |
| CRSP | two days later | -2.87% | final price |
| CRSP | three days later | +0.22% | final price |
| CRSP | three days earlier | +8.60% | final price |
| CRSP | five days earlier | +3.04% | final price |
| GILD | that day | -1.70% | final price |
| GILD | the next day | +2.38% | final price |
| GILD | two days later | -1.69% | final price |
| GILD | three days later | -1.64% | final price |
| GILD | three days earlier | -2.82% | final price |
| GILD | five days earlier | -6.65% | final price |
| NBIX | that day | +13.30% | final price |
| NBIX | the next day | +14.21% | final price |
| NBIX | two days later | +9.94% | final price |
| NBIX | three days later | +13.24% | final price |
| NBIX | three days earlier | +0.69% | final price |
| NBIX | five days earlier | +0.43% | final price |
| QGEN | that day | +0.10% | final price |
| QGEN | the next day | +0.95% | final price |
| QGEN | two days later | +1.04% | final price |
| QGEN | three days later | -0.03% | final price |
| QGEN | three days earlier | +0.05% | final price |
| QGEN | five days earlier | -0.29% | final price |
| XLV | that day | -0.34% | final price |
| XLV | the next day | +2.73% | final price |
| XLV | two days later | +0.31% | final price |
| XLV | three days later | +0.13% | final price |
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
Congressional trades in the stocks in this story
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 19 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 42 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 5 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 85 days before publication. Filed 4 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid the energy case looks
12 out of 100
“BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks” scores 12 out of 100. The score uses 1 sources.